Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs In Development, 2021 Research Report Featuring CombiGene, Gila Therapeutics, Takeda Pharmaceutical, XL-protein – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Drugs In Development, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules.

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor.

The report ‘Neuropeptide Y Receptor Type 2 – Drugs In Development, 2021’ outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity and Epilepsy.

Scope

• The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
• The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects
• The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics

Key Topics Covered:

Introduction

• Report Coverage

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Overview

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Therapeutics Development

• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Therapeutics Assessment

• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Companies Involved in Therapeutics Development

• CombiGene AB
• Gila Therapeutics Inc
• Takeda Pharmaceutical Co Ltd
• XL-protein GmbH

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Drug Profiles

CG-01 – Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

GT-001 – Drug Profile

GT-002 – Drug Profile

PYY-1119 – Drug Profile

XL-310 – Drug Profile

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Dormant Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Discontinued Products

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) – Product Development Milestones

Featured News & Press Releases

• Mar 04, 2021: BioStock: CombiGene advances preclinically and recruits post-doc
• Mar 01, 2021: The material from the first large-scale production of CG01 is now released for use in the final parts of the preclinical program
• Feb 09, 2021: Interview in BioStock, CombiGene on the International Epilepsy Day and the pharmaceutical authorities’ positive response
• Feb 03, 2021: Response from the Swedish and UK Pharmaceutical Regulatory Authorities confirms CombiGene’s plan for CG01’s final preclinical studies
• Jan 18, 2021: With the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01
• Dec 14, 2020: With the recruitment of Martin Linhult, CombiGene is starting the process to strengthen the company in preparation for the clinical studies in the epilepsy project CG01
• Oct 30, 2020: CombiGene comments the final preclinical steps
• Oct 01, 2020: CombiGene one step closer to clinical trials
• Sep 28, 2020: CombiGene launches large-scale production of CG01 for upcoming safety and biodistribution studies
• Sep 15, 2020: CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy
• Sep 11, 2020: CombiGene’s new agreement important for future clinical studies
• Sep 10, 2020: CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene’s gene therapy CG01
• Sep 10, 2020: CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene’s gene therapy CG01
• Sep 03, 2020: CombiGene signs production agreement with Spanish gene therapy manufacturer Viralgen
• Aug 18, 2020: Cobra Biologics completes production of Master Cell Banks for CombiGene’s epilepsy gene therapy drug candidate

Appendix

Companies Mentioned

• CombiGene AB
• Gila Therapeutics Inc
• Takeda Pharmaceutical Co Ltd
• XL-protein GmbH

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/x27x6s

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900